News & Features
Virginia Economic Review
Our quarterly publication, Virginia Economic Review, provides an insider look at Virginia’s economy, its diverse array of world-class companies, its amazing talent, and its stunning natural beauty, as well as insights from national thought leaders.
Filter by:
Best Medical Ships Crucial Cancer Therapies Worldwide, With VEDP’s Help
Best Medical International manufactures a crucial product that helps its users battle devastating cancers. Now, with an assist from VEDP, the company is getting its products into the hands of people who desperately need them.
04.01.2026
The Investments Behind a Biopharma Hotspot
A lot changed in Virginia’s life sciences industry in the space of about a month last fall. Between Sept. 16 and Oct. 20, biopharmaceutical manufacturing giants Eli Lilly and Company, AstraZeneca, and Merck & Co.
Building a Sustainable Pharma Manufacturing Workforce
Recent major biopharmaceutical manufacturing announcements are positioning Virginia for a broader reshoring effort in the pharma industry. COVID-era supply chain disruptions and resulting shortages exposed the risks of over-reliance on overseas production for essential medicines.
04.01.2026
Behind the Rise of a Research Center in Roanoke
Jenny Munson has surprised herself by launching not just one, but two businesses. Neither would have happened, the scientist believes, if she hadn’t moved her research program to Virginia Tech and the western Virginia city of Roanoke.
04.01.2026
Continuous Improvement
A pharmaceutical manufacturing innovation that came out of a Virginia university is changing the way medicines are made. The Commonwealth’s universities and the rest of its biopharma research community are making sure Virginia is ready to make the medicines of the future.
04.01.2026
Enabling Innovation
Would more men try to prevent unintended pregnancies if their choices for contraception went beyond a condom or vasectomy?
04.01.2026
Behind the Effort to Bring Drug Manufacturing Back to U.S. Shores
In October 2025, shovels went into the ground in Elkton, marking the start of a $3 billion pharmaceutical expansion project that will add 400,000 square feet to Merck’s existing campus.



